The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion
Open accessAbstract
Fluconazole in vitro susceptibility test results for 256,882 isolates of Candida spp. were collected from 142 sites in 41 countries from June 1997 to December 2007. Data were collected for 197,619 isolates tested with voriconazole from 2001 to 2007. A total of 31 different species of Candida were isolated. Increased rates of isolation of the common non- albicans species C. glabrata (10.2% to 11.7%), C. tropicalis (5.4% to 8.0%), and C. parapsilosis (4.8% to 5.6%) were noted when the time periods 1997 to 2000 and 2005 to 2007 were compared. Investigators tested clinical isolates of Candida spp. by the CLSI M44-A disk diffusion method. Overall, 90.2% of Candida isolates tested were susceptible (S) to fluconazole; however, 13 of 31 species identified exhibited decreased susceptibility (<75% S), similar to that seen with the resistant (R) species C. glabrata and C. krusei . Among 197,619 isolates of Candida spp. tested against voriconazole, 95.0% were S and 3% were R. About 30% of fluconazole-R isolates of C. albicans , C. glabrata , C. tropicalis , C. rugosa , C. lipolytica , C. pelliculosa , C. apicola , C. haemulonii , C. humicola , C. lambica , and C. ciferrii remained S to voriconazole. An increase in fluconazole resistance over time was seen with C. parapsilosis , C. guilliermondii , C. lusitaniae , C. sake , and C. pelliculosa . Among the emerging fluconazole-R species were C. guilliermondii (11.4% R), C. inconspicua (53.2% R), C. rugosa (41.8% R), and C. norvegensis (40.7% R). The rates of isolation of C. rugosa , C. inconspicua , and C. norvegensis increased by 5- to 10-fold over the 10.5-year study period. C. guilliermondii and C. rugosa were most prominent in Latin America, whereas C. inconspicua and C. norvegensis were most common in Eastern European countries. This survey identifies several less-common species of Candida with decreased susceptibility to azoles. These organisms may pose a future threat to optimal antifungal therapy and underscore the importance of prompt and accurate species identification and antifungal susceptibility testing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The actual proportion of C. albicans is well over 50–70% in Northern and Middle Europe, while mostly well below 50% in Southern Europe, Latin America, Australia, and the US.59,60”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [60]
In the citing paper
“For example, an increase in fluconazole resistance in naturally susceptible species such as C. parapsilosis, C. guilliermondii, C. lusitaniae, C. sake, and C. pelliculosa was observed in a population-based surveillance programme comprising more than 250,000 Candida strains isolated between 1997 and 2007 [43].”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [43]
In the citing paper
“With respect to CLSI clinical breakpoints, fluconazole resistance, defined as MIC values ≥8 mg/L for C. albicans, has been reported overall to be as high as 3.5%.43–48”
From Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans (2020) · cites this paper as [43]
In the citing paper
“About 1.4% of C. albicans isolates were resistant to fluconazole, of which 63.6% were cross-resistant to voriconazole.43”
From Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans (2020) · cites this paper as [43]
Citations
Cites
Manual of Clinical Microbiology.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-6-939_2 · Cited by 14,411
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“glabrata to develop resistance to both triazoles (2, 10, 12, 17, 27, 46, 55, 63).”
BackgroundSelf-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 3×
“These and other relatively rare species of Candida are unlikely to be familiar to many clinicians and microbiologists, and there are few or no data concerning prognosis or optimal treatment strategies (13, 14, 25, 41, 43, 47, 53, 54, 65, 66).”
BackgroundReference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard
Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,052
Candida parapsilosis, an Emerging Fungal Pathogen
Trofa, D., Gácser, A., & Nosanchuk, J. D. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00013-08 · Cited by 854 · cited 4×
“(69), and it is evident that when lapses in infection control”
BackgroundInfluentialPfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 694
Self-citationParczewska, O. K., Posaconazol, przeciwgrzybicze, L., Anidulafungina, Micafungina, & wrażliwość, O. (2009) · Cited by 656
New and emerging yeast pathogens
Hazen, K. C. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.4.462 · Cited by 614 · cited 1×
“ods, and the remainder used the classical methods alone (19, 21).”
MethodNucci, M., & Marr, K. A. (2005) · Clinical Infectious Diseases · doi:10.1086/432060 · Cited by 435 · cited 2×
“These and other relatively rare species of Candida are unlikely to be familiar to many clinicians and microbiologists, and there are few or no data concerning prognosis or optimal treatment strategies (13, 14, 25, 41, 43, 47, 53, 54, 65, 66).”
BackgroundPfaller, M. A., & Diekema, D. J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.t01-1-00844.x · Cited by 423 · cited 1×
“glabrata to develop resistance to both triazoles (2, 10, 12, 17, 27, 46, 55, 63).”
BackgroundSelf-citation
Research works printed but not linked: 1
- Pfaller, M. A., and D. J. Diekema. 2007. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J. Invasive Fungal Infect. 1 : 74-92.
Cited by
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Self-citationAzole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“In particular, patients with hematologic malignancies and bone marrow transplants have been shown to be at increased risk of C. krusei infection (Merz et al., 1986; Wingard et al., 1991; Pfaller et al., 2008).”
BackgroundPfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
“We have shown variable cross-resistance between fluconazole and voriconazole when tested against the common species of Candida causing IC [53, 63, 64].”
BackgroundMethodSelf-citationEmerging opportunistic yeast infections
Miceli, M. H., Díaz, J. A., & Lee, S. A. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70218-8 · Cited by 811
Metadata
- Authors
- Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A.
- Affiliations
- Departments of Pathology
- University of Iowa (US)
- Giles Scientific, Inc., Santa Barbara, California
- Women's and Children's Hospital (AU)
- University of Turin (IT)
- Leipzig University (DE)
- Husa Shan Hospital, Shanghai, China
- Singapore General Hospital (SG)
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2010-04
- Volume
- 48
- Issue
- 4
- Pages
- 1366-1377
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC2849609
- OpenAlex
- W2122716163
- Cited by
- 718
- References
- 75
- Citations by year
- 2026: 27 · 2025: 30 · 2024: 33 · 2023: 40 · 2022: 44 · 2021: 41 · 2020: 40 · 2019: 49 · 2018: 56 · 2017: 56 · 2016: 36 · 2015: 39 · 2014: 57 · 2013: 37 · 2012: 46
- FWCI
- 31.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida, antifungal resistance, fluconazole resistance, voriconazole resistance, Candida glabrata, Candida tropicalis, Candida parapsilosis, Candida guilliermondii, Candida inconspicua, Candida rugosa, Yarrowia lipolytica, Candida pelliculosa, Candida krusei, Candida albicans, non-albicans Candida, emerging fungal pathogens
- MeSH terms
- Antifungal Agents, Candida, Candidiasis, Humans, Microbial Sensitivity Tests, Pyrimidines, Triazoles, Fluconazole, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion. https://app.cochat.ai/papers/10.1128/jcm.02117-09
- The paper
- Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010). Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.02117-09
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.